Early Chemotherapy in Asymptomatic Metastatic Colorectal Cancer
Author Information
Author(s): Stephen P Ackland, Mark Jones, Dongsheng Tu, John Simes, Jennifer Yuen, Ann-Marie Sargeant, Harminder Dhillon, Richard M Goldberg, Elham Abdi, Lois Shepherd, Malcolm J Moore
Primary Institution: Australasian Gastro-Intestinal Trials Group and NSW Clinical Oncology Group
Hypothesis
Does starting chemotherapy immediately in asymptomatic patients with metastatic colorectal cancer improve survival and quality of life compared to delaying treatment until symptoms develop?
Conclusion
Early treatment of asymptomatic patients with metastatic colorectal cancer did not provide a survival benefit or improved quality of life compared to withholding treatment until symptoms occurred.
Supporting Evidence
- Median survival was 13.0 months for immediate treatment and 11.0 months for delayed treatment.
- Quality of life scores showed no significant difference between immediate and delayed treatment groups.
- Only 70% of patients in the delayed treatment group received protocol therapy.
Takeaway
This study looked at whether giving chemotherapy right away to patients with cancer who don't have symptoms helps them live longer or feel better. It found that waiting until they have symptoms is just as good.
Methodology
A meta-analysis combining two randomised trials comparing immediate versus delayed chemotherapy in asymptomatic patients with metastatic colorectal cancer.
Potential Biases
Potential bias due to patient preference for treatment timing and compliance issues with the delayed treatment group.
Limitations
The study was limited by slow patient accrual, leading to a smaller sample size than intended, which may affect the power to detect differences.
Participant Demographics
Patients were asymptomatic with metastatic colorectal cancer, with a median age around 66 years, and included both Australasian and Canadian participants.
Statistical Information
P-Value
P=0.49 for survival comparison, P=0.73 for progression-free survival comparison.
Confidence Interval
95% CI 0.79–1.72 for survival, 95% CI 0.71–1.64 for progression-free survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website